Target intelligence / Profile preview

Bacterial 23S ribosomal RNA domain V (23S rRNA domain V)

Target
23S rRNA domain V
Molecular classification
Ribosomal RNA, Nucleic acid, Ribozyme
01

Overview

The bacterial 23S ribosomal RNA (rRNA) domain V is a central component of the 50S large ribosomal subunit, serving as the catalytic core of the peptidyl transferase center (PTC) (Nissen et al., Science, 2000). This domain is responsible for facilitating peptide bond formation between the aminoacyl-tRNA in the A-site and the peptidyl-tRNA in the P-site during protein translation (Beringer and Rodnina, Molecular Cell, 2007). Additionally, domain V forms the entrance to the nascent peptide exit tunnel (NPET), which guides the growing polypeptide chain out of the ribosome (Wilson, Nature Reviews Microbiology, 2014). Due to its essential role in bacterial survival, it is a major target for diverse classes of antibiotics, including macrolides, lincosamides, streptogramins, oxazolidinones, and pleuromutilins (Schlünzen et al., Nature, 2001). These drugs exert their antimicrobial effects by binding to specific nucleotides within domain V, thereby obstructing the exit tunnel or inhibiting the catalytic activity of the PTC (Dunkle et al., PNAS, 2010). Resistance to these antibiotics often arises through point mutations in the 23S rRNA or through the action of methyltransferases that modify specific residues, such as A2058, to prevent drug binding (Vester and Douthwaite, Antimicrobial Agents and Chemotherapy, 2001).

Other names
Peptidyl transferase centerPTCDomain V of 23S rRNA23S rRNALarge ribosomal subunit RNA
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the peptidyl transferase center or the nascent peptide exit tunnel, preventing peptide bond formation or blocking the progression of the growing polypeptide chain.

03

Biological functions

Protein synthesisPeptidyl transferase activityPeptide bond formationRibosome assemblyNascent peptide exit tunnel formation
04

Disease associations

Bacterial infection
05

Safety considerations

Antibiotic resistance developmentMitochondrial protein synthesis inhibition (due to structural similarity with human mitochondrial ribosomes)Gastrointestinal dysbiosisDrug-drug interactions (e.g., MAO inhibition with oxazolidinones)
06

Interacting drugs

Erythromycin

11 more in the full profile.

07

Biomarkers

23S rRNA A2058 mutation23S rRNA A2059 mutationErm methylase expressionCfr methyltransferase presence

Beyond the preview

Go deeper on Bacterial 23S ribosomal RNA domain V (23S rRNA domain V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial 23S ribosomal RNA domain V (23S rRNA domain V).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call